In the BioHarmony Drug Report Database

"Preview" Icon

Ubrogepant

Ubrelvy (ubrogepant) is a small molecule pharmaceutical. Ubrogepant was first approved as Ubrelvy on 2019-12-23. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. It is known to target calcitonin gene-related peptide type 1 receptor. Ubrelvy’s patents are valid until 2035-01-30 (FDA).

 

Trade Name

 

Ubrelvy
 

Common Name

 

ubrogepant
 

ChEMBL ID

 

CHEMBL2364638
 

Indication

 

migraine disorders, migraine with aura, migraine without aura
 

Drug Class

 

Calcitonin gene-related peptide receptor antagonists

Image (chem structure or protein)

Ubrogepant structure rendering